Ankur M. Sharma

Ankur M. Sharma

Auto-generated profile, based on publicly available information

Ankur M. Sharma

Radiology, Massachusetts General Hospital, Boston, MA, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Practical Radiation Oncology
Verified
Journal Article
Closed access
WCWilliam Clinkscales
William Clinkscales
MSMatthew Spence
Matthew Spence
JGJohn Gleysteen
John Gleysteen
NHNeil Hayes
Neil Hayes
EIEnrique Izaguirre
Enrique Izaguirre
ASAnkur M. Sharma
Ankur M. Sharma

1 October 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
PMP. McGeachy
P. McGeachy
DSD.K. Sasaki
D.K. Sasaki
CHC. Harris
C. Harris
ASA.M. Sharma
A.M. Sharma
ADA. Dubey
A. Dubey
Purpose/Objective(s) 3D printing continues to present innovative applications in radiotherapy (RT). One such application is the creation of 3D printed bolus for RT treatments. However, the increased accuracy provided by these 3D prints requires additional scrutiny with respect to their quality and fit. To date, there exists no widely available set of quality assurance (QA) tests for these 3D printed devices, which are seeing increased use in RT. Therefore, this study looks at formulating a comprehensive set of tests for the quality of 3D printed bolus, thus ensuring they perform as intended in RT treatments. Materials/Methods QA was performed on seven 3D printed boluses used for various treatment sites. The shape, bulk density, and defect characteristics were used to assess 3D print quality. For each bolus, a high resolution (0.8 mm slice thickness) CT scan was acquired. The scan was imported into the planning system, where an external contour was defined. For the bulk density test, the mean Hounsfield Unit (HU) of a volume of interest (VOI) was compared with the expected HU (HUexpected). This VOI was cropped 1 mm inwards from the external contour to avoid any partial volume effects. The max and min HUs from the VOI were used to identify print defects, paying particular attention to min HU < 0 and max HU > HUexpected. The shape of the print was assessed by comparing the external contour with the original mesh used to create the 3D print. After registering the two structure sets, the congruence in shape was quantified through calculating Hausdorff distances between structure sets, and evaluating the resulting median, min, and max errors. Results For bulk density, the set of 3D printed boluses yielded a mean HU of 127 which, on average, was 7 HUs higher than the HUexpectedof 120. For 3D print defects, the (max, min) HUs from the set of 3D prints was (211, -300). The max HU > HUexpected is most likely due to the presence of noise. HU values < 0 (e.g. min HU) were typically observed along the edge of the 3D print, where the extruder is changing between fill patterns, causing small air gaps. For the shape of the 3D prints, the Hausdorff distances yielded average (median, max, min) errors of (0.21, 2.26, 0.00) mm. The larger errors (e.g. max error) were observed in regions where a noticeable change in 3D print shape was observed (e.g. around the nose and eyes). This information may be used to map out potentially troublesome areas. Conclusion A comprehensive set of QA tests has been presented for 3D printed bolus used in RT. The robustness of these tests was demonstrated through application on a variety of 3D prints. This QA will aid in standardizing 3D print quality in RT. As this QA set is the first of its kind, it can be adopted by programs commissioning and performing regularly scheduled QA for 3D printed bolus.

2 May 2022
Verified
Conference Paper
Closed access
SBS.R. Berigei
S.R. Berigei
BFB. Flashner
B. Flashner
SNSreyankar Nandy
Sreyankar Nandy
RRR.A. Raphaely
R.A. Raphaely
ASA. Sharma
A. Sharma
LHL.P. Hariri
L.P. Hariri

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
KJKate Johnson
Kate Johnson
ADArbind Dubey
Arbind Dubey
DSDavid Sasaki
David Sasaki
DRDaniel Rickey
Daniel Rickey
CHChad Harris
Chad Harris
RKRashmi Koul
Rashmi Koul
CARO 2016 S29 _________________________________________________________________________________________________________ cardiac four-dimensional CT (4D-CT) synchronized to the electrocardiogram were obtained in treatment position, using a prospective sequential acquisition method including the extreme phases of systole and diastole. On a MimVista® image registration workstation, dose distributions were transferred to the cardiac 4D-CT. The left coronary artery, left ventricle and heart were contoured on both phases of the cardiac cycle. The maximum and minimum doses to the left coronary, left ventricle and heart were compared using a bilateral paired Student T test. Results: Preliminary data from the first eight patients enrolled are presented. Median age was 60 years (56-71) and median planned dose to the left breast was 42.56 Gy (42.56-50) in 16 fractions (16-20). For the left coronary artery, mean dose, V5 and V20 in systole versus diastole were 6.1 Gy versus 7.9 Gy (p = 0.02), 37% versus 48% (p = 0.02) and 10% versus 16% (p = 0.04), respectively. For the left ventricle, mean dose, V5 and V20 in systole versus diastole were 1.3 Gy versus 1.6 Gy (p = 0.005), 6% versus 9% (p = 0.03) and 1% versus 2% (p > 0.1), respectively. For the whole heart, mean dose, V5 and V20 in systole versus diastole were 0.9 Gy versus 1.3 Gy (p = 0.005), 21 cc versus 32 cc (p = 0.07) and 4 cc versus 5 cc (p > 0.1), respectively. Conclusions: Beyond DIBH, systolic irradiation would be associated with a further reduction in V5, V20 and mean dose to the left coronary artery, as well as a reduction in V5 and mean dose to the left ventricle and heart as a whole. The potential clinical impact of this reduction as well as the feasibility of cardiac gated irradiation are to be further investigated.

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
ASAnkur Sharma
Ankur Sharma
ADArbind Dubey
Arbind Dubey
ALAhmet Leylek
Ahmet Leylek
DRDaniel Rickey
Daniel Rickey
DSDavid Sasaki
David Sasaki
BMBoyd McCurdy
Boyd McCurdy
CARO 2016 S33 _________________________________________________________________________________________________________ Severe late toxicity involving the lungs, kidneys and thyroid was relatively low. The risk of second cancers was acceptable. Our study indicates that this approach is both safe and effective.

1 November 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
NAN. Ahmed
N. Ahmed
MLMichelle Lobchuk
Michelle Lobchuk
WHW. Hunter
W. Hunter
PJP. Johnston
P. Johnston
ZNZ. Nugent
Z. Nugent
JSJ. Sisler
J. Sisler
Do Not Resuscitate (DNR) is a significant but challenging part of end of life discussions when dealing with incurable lung cancer patients. We have attempted to explore the perceptions and preferences of patients, their caregivers (CGs) and health care providers (HCPs), and the current practice and opinions on DNR discussion in a multidisciplinary lung cancer clinic.